Alzheimer's Treatment Progress Depends on More Than Just Scientific Discoveries

Sat, 02 May 2026 17:58:00 +0200

Alzheimer’s research is entering a critical phase where decades of scientific effort are starting to yield tangible results. Pioneering researcher John Hardy, speaking at WIRED Health, highlighted the advancements in treatment, notably drugs like Lecanemab and Donanemab, which have shown potential to slow cognitive decline in Alzheimer’s patients. However, Hardy emphasizes that breakthroughs in science are not enough. Better diagnosis, particularly through the use of biomarkers and genetics, is crucial to improving Alzheimer’s care. He stresses the importance of political will to fund dementia services and ensure that accurate diagnoses are made, noting that many people are misdiagnosed with dementia instead of Alzheimer’s specifically. Hardy also discussed the ongoing debate about the role of amyloid deposits in Alzheimer’s, a key protein involved in the disease’s progression. While drugs targeting amyloid are showing promise, they only slow the disease rather than stopping it entirel